Parkinson's disease historical perspective
|
Parkinson's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parkinson's disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Parkinson's disease historical perspective |
|
Risk calculators and risk factors for Parkinson's disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Parkinson disease’s symptoms have been known for many years but the first person who documented and recognized Parkinson’s disease was a British physician, James Parkinson in 1817 who named it paralysis agitans. The current name of the disease (Parkinson disease) is from Jean-Martin Charcot. The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients. Later on in 1919 Tretiakoff showed that in this patients’ substantia nigra there are evidences of neuronal loss. Finally in the 1950s dopamine depletion was known to be the underlying cause of the disease.[1] Later, in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.[2][3][4]
References
- ↑ Hornykiewicz O (2006). "The discovery of dopamine deficiency in the parkinsonian brain". J. Neural Transm. Suppl. (70): 9–15. PMID 17017502.
- ↑ Manyam BV, Sánchez-Ramos JR (1999). "Traditional and complementary therapies in Parkinson's disease". Adv Neurol. 80: 565–74. PMID 10410773.
- ↑ Parkinson J (2002). "An essay on the shaking palsy. 1817". J Neuropsychiatry Clin Neurosci. 14 (2): 223–36, discussion 222. doi:10.1176/jnp.14.2.223. PMID 11983801.
- ↑ Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520.<ref name="pmid5637779">Cotzias GC (March 1968). "L-Dopa for Parkinsonism". N. Engl. J. Med. 278 (11): 630. PMID 5637779.